Schizophrenia Clinical Trials in Decatur, Georgia

13 recruitingDecatur, Georgia

Showing 113 of 13 trials

Recruiting
Phase 2

Study to Assess the Safety, Tolerability, and Treatment Response of GXV813 in Hospitalized Adults With Schizophrenia

Schizophrenia
Novartis Pharmaceuticals142 enrolled7 locationsNCT07467993
Recruiting
Phase 3

A Trial of the Efficacy and Safety of SEP-363856 in Acutely Psychotic Participants With Schizophrenia

Schizophrenia
Otsuka Pharmaceutical Development & Commercialization, Inc.522 enrolled73 locationsNCT06894212
Recruiting
Phase 3

NBI-1117568-SCZ3032: Long-Term Evaluation of NBI-1117568 in Adults With Schizophrenia

Schizophrenia
Neurocrine Biosciences800 enrolled53 locationsNCT07114874
Recruiting
Phase 1

Determining Efficacy and Safety of BXCL501 in Agitation Associated With Pediatric Schizophrenia and Bipolar Disorder

Schizophrenia
BioXcel Therapeutics Inc140 enrolled5 locationsNCT05025605
Recruiting
Phase 3

An Extension Study to Assess Long-Term Safety and Tolerability of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of Schizophrenia

Schizophrenia
Karuna Therapeutics, Inc., a Bristol Myers Squibb company280 enrolled175 locationsNCT05304767
Recruiting
Phase 2

A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Inpatient Adults With Schizophrenia

Schizophrenia
MapLight Therapeutics300 enrolled25 locationsNCT07038876
Recruiting
Phase 3

NBI-1117568-SCZ3029: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia

Schizophrenia
Neurocrine Biosciences284 enrolled21 locationsNCT06963034
Recruiting
Phase 3

Study to Evaluate Weight Gain as Assessed by Change in BMI Z-score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder

SchizophreniaBipolar I Disorder
Alkermes, Inc.220 enrolled47 locationsNCT05303064
Recruiting
Phase 1

A Study to Evaluate the Dose Levels, Safety, and Drug Levels of Single KarXT Intramuscular Injection in Participants With Schizophrenia

Schizophrenia
Bristol-Myers Squibb48 enrolled8 locationsNCT07061288
Recruiting
Phase 2

A Study to Evaluate KYN-5356 in Adults With Cognitive Impairment Associated With Schizophrenia

Cognitive Impairment Associated With Schizophrenia (CIAS)
Kynexis B.V.150 enrolled13 locationsNCT07191483
Recruiting
Phase 3

Safety and Tolerability Trial of Lumateperone in Pediatric Patients With Schizophrenia, Bipolar Disorder or Autism Spectrum Disorder

SchizophreniaAutism Spectrum DisorderBipolar Disorder
Intra-Cellular Therapies, Inc.500 enrolled50 locationsNCT06229210
Recruiting
Phase 4

Safety and Tolerability of Open-Labeled Iloperidone in Adolescents

SchizophreniaBipolar I Disorder
Vanda Pharmaceuticals100 enrolled9 locationsNCT05648591
Recruiting
Phase 3

Safety and Efficacy of Brilaroxazine (RP5063) in Schizophrenia

Schizophrenia
Reviva Pharmaceuticals690 enrolled18 locationsNCT05184335